4D Molecular Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report0 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
4D Molecular Therapeutics has 3 disclosed suppliers and 3 disclosed customers in SEC filings.
+4.64%
vs ±30.9% implied · ×0.15
shaded = implied · ▲▼ = realized
4D Molecular Therapeutics, Inc.
11.98
SentenceIn October 2025, we announced a funding agreement with the Cystic Fibrosis Foundation ("CFF") to provide up to $11 million in additional funding, including $7.5 million in an initial tranche, which was completed in October 2025.
FDMT 10-Kaccession 0001193125-26-114075
SentenceFor example, we rely on our exclusive license agreements with (i) U.C. Berkeley for certain rights with respect to the intellectual property covering certain compositions of matter and methods of use of certain AAV variants related to our 4D-710 and 4D-725 product candidates, and (ii) University of Pennsylvania for certain rights with respect to the intellectual property covering certain compositions of matter and methods of use of the short-form human complement factor H (sCFH) payload related to our 4D-175 product candidate.
FDMT 10-Kaccession 0001193125-26-114075
SentenceFor example, we rely on our exclusive license agreements with (i) U.C. Berkeley for certain rights with respect to the intellectual property covering certain compositions of matter and methods of use of certain AAV variants related to our 4D-710 and 4D-725 product candidates, and (ii) University of Pennsylvania for certain rights with respect to the intellectual property covering certain compositions of matter and methods of use of the short-form human complement factor H (sCFH) payload related to our 4D-175 product candidate.
FDMT 10-Kaccession 0001193125-26-114075
As partial consideration for the rights and licenses granted to AGT under the License Agreement, we received an upfront payment of $20.0 million.
FDMT 10-Kaccession 0001193125-26-114075
SentenceOtsuka made an upfront cash payment of $85 million and agreed to provide certain cost sharing for global development activities.
FDMT 10-Kaccession 0001193125-26-114075
Linked news
NewsExpected move
No implied move.